Credit Suisse is out with a research report on Edwards Lifesciences Corp. EW and it has a Neutral rating and a $99 price target on shares.
In a note to clients, Credit Suisse writes, "Initiating at Neutral with a $99 price target: EW is a worldwide leader in the surgical and transcatheter aortic valve implant (TAVI) markets. While we expect strong TAVI growth to continue (we project 34% TAVI growth for EW and 33% market growth through 2015), we believe this growth is already reflected in EW's premium valuation, which drives our Neutral rating."
Shares of EW closed at $89.69 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetInitiationAnalyst RatingsCredit SuisseHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in